key: cord-0900004-vofiohbg
authors: Perocheau, Dany; Touramanidou, Loukia; Gurung, Sonam; Gissen, Paul; Baruteau, Julien
title: Clinical applications for exosomes: Are we there yet?
date: 2021-05-03
journal: Br J Pharmacol
DOI: 10.1111/bph.15432
sha: c7920436703c38a05c3544456d22cf896c4e15c6
doc_id: 900004
cord_uid: vofiohbg

Exosomes are a subset of extracellular vesicles essential for cell–cell communication in health and disease with the ability to transport nucleic acids, functional proteins and other metabolites. Their clinical use as diagnostic biomarkers and therapeutic carriers has become a major field of research over recent years, generating rapidly expanding scientific interest and financial investment. Their reduced immunogenicity compared to liposomes or viral vectors and their ability to cross major physiological barriers like the blood–brain barrier make them an appealing and innovative option as biomarkers and therapeutic agents. Here, we review the latest clinical developments of exosome biotechnology for diagnostic and therapeutic purposes, including the most recent COVID‐19‐related exosome‐based clinical trials. We present current exosome engineering strategies for optimal clinical safety and efficacy, and assess the technology developed for good manufacturing practice compliant scaling up and storage approaches along with their limitations in pharmaceutical industry.

. These components are a signature for their cell origin and their composition can alter their pharmacokinetic attributes (Kalluri & LeBleu, 2020) . Exosomes are extracellular vesicles (Pan & Johnstone, 1983 ) generated in the cytoplasm in the multivesicular body, which is defined by the presence of intraluminal vesicles originating from inward budding into the endosomal lumen. Multivesicular bodies get transported to the plasma membrane leading to fusion with the cell surface whereby the intraluminal vesicles get secreted as exosomes (Colombo et al., 2014) .

Extracellular vesicles are classified into three groups based on their sizes:-exosomes (40-160 nm) (Kalluri & LeBleu, 2020) , microvesicles (100-1000 nm) and apoptotic bodies (>1000 nm) (Andaloussi et al., 2013; Pegtel & Gould, 2019) . The size and marker overlap between exosomes and microvesicles, and make their differentiation complex (Corso et al., 2017; Doyle & Wang, 2019) . However, the International Society for Extracellular Vesicles (ISEV) proposes a series of references to characterise exosomes based on their function or composition (Théry et al., 2018) . Their reduced immunogenicity compared to liposomes or viral vectors, and their ability to cross major physiological barriers like the blood-brain barrier make them an attractive and innovative option as biomarkers and therapeutic agents ( Figure 1 ). Indeed exosomes, which are present in a wide range of body fluids, could be ideal biomarkers particularly for early detection of diseases. To support translation and ever-expanding portfolio of clinical trials, various strategies are being developed to optimise cargo loading, improve cell type targeting and increase exosome uptake.

Good manufacturing practice of exosomes requires robust scaling up and storage processes (Whitford & Guterstam, 2019) .

Here, we review the latest clinical developments of exosome biotechnology for diagnostic and therapeutic purposes, including the most recent COVID-19-related exosome-based clinical trials. We present current exosome engineering strategies for optimal clinical safety and efficacy and assess the technology developed for good manufacturing practice compliant scaling up and storage approaches along with their limitations.

Exosomes released in pathophysiological conditions such as inflammation, neurodegeneration, immune response, cancer, cell death or angiogenesis contain constitutive components, including transmembrane proteins or nucleic acids that can act as biomarkers for clinical diagnosis, staging disease severity or assessing therapeutic response (Table 1 ) (Hardy et al., 2019; Howitt & Hill, 2016; Jiang et al., 2016; Kitai et al., 2017; Waldenström & Ronquist, 2014; Wu et al., 2016) .

Some of the tetraspanins, such as CD9, CD63, CD81 and CD151, often found at the exosomal membranes (Hoshino et al., 2015; Thery et al., 2002) can be used as screening tools in health and disease. For example, increased CD81 correlates with fibrosis progression and has been proposed as a diagnostic biomarker for complications in viral hepatitis C Welker et al., 2012) .

The secretion of extracellular vesicles from different types of tumour cells is a significant method of conditioning and altering the tumour microenvironment by malignant cells (Harris et al., 2015) .

Although exosomes are produced by most cell types, observations support the increased secretion of exosomes under pathological conditions, such as cancer (Ohno et al., 2013) . Proteomic analysis of those exosomes secreted under various physiological and pathological conditions has shown significant changes in protein expression F I G U R E 1 From mode of actions to therapies. Exosomes are promising players where their polymorph uses (orange) can influence their purpose (green) in clinical settings (Duijvesz et al., 2013; Lee et al., 2016) . Proteins from various cancers are also involved in similar biological processes and functions. A study performed gene ontology analysis on a variety of differentially expressed proteins derived from exosomes. Results suggested that those proteins were involved in similar biological mechanisms, such as cell adhesion, migration and transport (Sherman & Lempicki, 2009 ).

Contribution of exosomal proteins to angiogenesis, metastasis, tumour formation and disease makes them appealing biomarkers for diagnosis or prognosis applications in cancer, for example, lysosomalassociated membrane protein 3 (LAMP-3; also known as CD63) in ovarian cancer, lung cancer and melanoma (Hurwitz et al., 2016; Pols & Klumperman, 2009) , epidermal growth factor receptor (EGFR) in glioblastoma (Skog et al., 2008) , proteoglycan glypican-1 in early stage of pancreatic cancer (Melo et al., 2015) and proteins associated with the EGFR pathway, such as retinoic acid-induced protein 3, Gs-α subunit and resistin in bladder cancer and kidney disorders (Smalley et al., 2008; Zhou et al., 2008) .

In neurodegeneration, exosomal aggregation-prone protein amyloid-β peptide (amyloid β) and exosome-associated tau phosphorylated at Thr-181 are established diagnostic biomarkers for Alzheimer's disease (Rajendran et al., 2006; Saman et al., 2012) .

Autolysosomal proteins like cathepsin D, LAMP or α-synuclein are proposed diagnostic markers for early-stage Parkinson's disease (Alvarez-Erviti, Couch, Richardson, et al., 2011; Alvarez-Erviti, Seow, Schapira, et al., 2011; Alvarez-Erviti, Seow, Yin, et al., 2011; Goetzl et al., 2015; Lemprière, 2020 (Niu et al., 2020) , highlighting the exosomal counterpart to be a more sensitive diagnostic and severity scoring tool.

Exosomes also incorporate nucleic acids such as messenger RNA (mRNA), micro-RNA (miRNA), small interfering RNA (siRNA) and

p-element-induced wimpy testis (PIWI)-interacting RNA (piRNA) that display mutations in the host cell (Han et al., 2017; Shtam et al., 2013; Thakur et al., 2014; Valadi et al., 2007) . The early detection of a tumour is crucial for successful treatment. In addition to tissue biopsy- pathophysiology (Sharma, 2018) . Several studies have focused their analysis on circulating miRNA from enriched exosomes. A recent study showed that exosomal miR-141 was progressively increased in prostatic hypertrophy, localised prostate cancer and metastatic disease, suggesting a potential diagnostic or prognostic role (Li et al., 2016) . A different project compared the performance of whole blood miRNA with exosomal miRNA analysis. The results presented that miR-375 derived from whole plasma could differentiate pancreatic cancer from benign prostatic hyperplasia patients, while exosomal miR-200c-3p

and miR-21-5p were better discriminators and Let-7a-5p miRNA in exosomes could distinguish pancreatic cancer patients with different severity scores (Endzeliņš et al., 2017) . miRNA-375 levels in exosomes from squamous cells of carcinoma patients determine the progression from local inflammation to carcinoma and are potential early-stage biomarkers for oral carcinoma . Exosomal miRNA-20a-5p, miRNA-24-3p, miRNA106a-5p, miRNA-891a and miRNA-1908 in nasopharyngeal carcinoma affect both cell differentiation and expansion by down-regulating the mitogen-activated protein kinase-1 (MARK1) signalling pathway, hence their prognostic application (Ye et al., 2014) . Similarly, exosomal mRNAs can be used as diagnostic biomarkers in body fluids reducing the impact and cost of surgical biopsies (Rabinowits et al., 2009; Taylor & Gercel-Taylor, 2008) .

For example, saliva-derived exosomes (Lau et al., 2013) , human amniotic fluid-derived exosomes and urine-derived exosomes (Keller et al., 2007) and invasion and could be used as prognostic and diagnostic markers in cancer development (Martinez et al., 2015) . Various studies have also showed that piRNAs could be valuable markers for cancer metastasis, for example, piR-4987 in lymph node metastasis (Huang et al., 2013) , piR-932 and PIWIL2 in metastasis of breast cancer and piR-32051, piR-39894, and piR-43607 in clear cell renal cell carcinoma metastasis, late clinical stage and poor cancer-specific survival (Fu et al., 2015) . Recent publications have questioned whether some RNA detected in exosome preparations could be derived from culture media, particularly when using sera, following the most accepted purification method based on ultracentrifugation (Tosar et al., 2017; Wei et al., 2016) .

While the vast majority of ongoing exosome-based clinical trials aims at identifying diagnostic or prognostic biomarkers (Table 1) (Table 2) .

Different exosome-based approaches can be used for cancer therapies like oncogene inhibition. For example, the phase I trial (Andrews et al., 2001) . No results have been disclosed yet.

Exosomes are promising delivery agents to treat inflammatory disorders due to their low immunogenicity, intrinsic anti-inflammatory immune balance (Nassar et al., 2016; Zhao et al., 2012) . No results have been disclosed yet.

Exosomes have the advantages of being able to cross the blood-brain barrier, a critical step for brain-targeted therapies. This property has been exploited in diseases such as Parkinson (Haney et al., 2015) or ischemic stroke. Recently, studies have shown that nanoparticles Lv et al., 2018) but also exosomes can be used as a therapeutic agent for the treatment of ischemic stroke where an engineered c(RGDyK)-conjugated exosomes were able to target the lesion of the ischemic brain following intravenous injections (Tian et al., 2018) . Reperfusion can be the only option to reverse brain damage following a stroke, but this can induce an inflammatory reaction potentially causing further damage. This is how Dong et al. (2019) suggested the use of neutrophil membrane-derived vesicles loaded with resolvin D2, acting as anti-inflammatory agent and specifically delivered to the brain and in particular to a stroke lesion.

Exosome-based technologies to generate vaccines have been exploited for years (Devhare & Ray, 2017) . Exosomes have been explored as a platform for vaccination, by delivering diseaseassociated antigens. This approach was tested by delivering hepatitis C-associated antigens (Desjardins et al., 2009 ) and extended to the patients.

Exosomes are being widely investigated as immunomodulators or therapeutic cargo vehicles. This intense research field is continuously refining engineering strategies to optimise efficacy and/or delivery. A specific targeting of the recipient cell is paramount to adequately deliver exosome content (Horibe et al., 2018) . This is mediated by the Incorporation of pH-sensitive peptides such as the alphagalactosidase A protein can be used to enhance membrane fusion.

Alpha-galactosidase A protein creates an α-helix formation upon endocytosis and subsequent pH reduction (Nakase & Futaki, 2015) .

Similarly, exosome membrane while coupled with 3-(diethylamino)

propylamine results in membrane disruption in an acidic environment resulting in enhanced cytosolic release of the cargo (Lee, Park, et al., 2019) .

Extracellular vesicles including exosomes are being targeted by plasma proteins making them prone to rapid clearance during circulation. Polyethylene glycol (PEG) adjunction to the outer membrane of exosomes can act as a shield to protect vesicles from clearance (Antimisiaris et al., 2018) . However, this can hinder interactions between target cells and exosomes. To counteract this, PEG-conjugated antibodies or "nanobodies" against EGFR are added onto the exosomal membrane increasing the circulation time and binding to EGFR overexpressing tumour cells (Kooijmans et al., 2016) .

Based on their natural capacity to transfer cargo such as proteins or nucleic acids, exosomes can be engineered as a therapeutic vehicle.

However, mechanisms for loading such cargoes into exosomes are F I G U R E 2 Engineering strategies to refine a specific function and/or tropism to exosomes. Depending on their parent cell line, exosomes can express intrinsic ligands or can be engineered to express specific targeting ligands, stimuli response peptide, fusion protein, immune-evasive components, or viral glycoproteins. Their cargos can vary from small-sized genetic material such as noncoding RNAs to components as large as AAV. Exosome engineering can enable specific targeting of the central nervous system, systemic organs, or tumours. AAV: adeno-associated vector, HEK: human embryonic kidney, MSC: mesenchymal stem cells, PEG: polyethylene glycol, TRAIL: TNF-related apoptosis-inducing ligand challenging. This is why recent efforts are being developed to maximise exosomal cargo loading and cargo refinement for increased therapeutic benefit. This can be achieved by creating exosome scaffolds like the prostaglandin F2 receptor negative regulator protein and the brain acid soluble protein 1 (Codiak Ltd., 2021) Similarly, genetic materials such as miRNAs are naturally present in exosomes but at levels unlikely to exert detectable effects (Chevillet et al., 2014) . This is why strategies have been developed to overexpress them in exosomes to mediate posttranscriptional regulation in recipient cells. For example, this involves miRNA-126 acting as miRNA mimic to supress the PTEN/PI3K/AKT signalling pathway involved in cancer proliferation and migration (Nie et al., 2020) . In another application in cancer, exosomes are used as specific drug vehicle delivering doxorubicin, paclitaxel or curcumin with a better efficacy and reduced off-target toxicity compared to treatment with drug alone (György et al., 2015; Mentkowski et al., 2018) . To tackle chemotherapy resistance, exosomes are used for co-delivery of chemotherapeutic drug and chemoresistance inhibitors using miRNA inhibitors to modulate the expression of tumour suppressor genes.

For instance, exosomes loaded with 5-fluorouracil (5-FU) against colorectal cancer and miR-21 inhibitor (miR-21-i) successfully reduced miR-21-mediated 5-FU resistance in 5-FU-resistant colorectal cancer cell line (Liang et al., 2020) . Similar technologies can be developed to deliver other genetic materials such as siRNAs which have therapeutic applications in gene silencing or the CRISPR-Cas gene editing systems. This is of particular interest for the treatment of neurological diseases due to the exosome's ability to cross the blood-brain barrier.

Exosome-mediated delivery of siRNA against BACE1 or the vascular endothelial growth factor (VEGF) resulted, respectively, in a strong reduction of BACE1 (Alvarez-Erviti, Seow, Yin, et al., 2011) or VEGF (Yang, Fogarty, et al., 2017) reduction in the mouse brain (Alvarez-Erviti, Seow, Yin, et al., 2011) . CRISPR-Cas systems can also be delivered using exosomes instead of viral vectors where safety and logistical challenges to package such large cargoes have created limitations for wider use (Kim et al., 2017; Knott & Doudna, 2018) .

The ability of exosomes in protecting their content against degradation is another advantage for some cargoes such as adeno-associated vector-mediated vectors. This system protects adeno-associated vectors against specific capsid humoral immunity in preimmunised patients, an increasing issue in adeno-associated vector gene therapy (Perocheau et al., 2019) . A subpopulation of adeno-associated vectors originally from the media of manufacturing cells is physiologically encapsulated into exosomes creating exosomes-associated adeno-associated vectors (exo-adeno-associated vectors) (György & Maguire, 2018) . Exosomes-associated adeno-associated vectors enable successful transduction in vivo despite low titres of neutralising antibodies, where wild-type adenoassociated vectors are neutralised by humoral immunity.

The origin of the exosome-producing cells influence the exosome biodistribution and its therapeutic effect. Tumour-derived exosomes have preferential tropism towards their parent cell type allowing a direct application in their native form to target these tumour cells (Sun et al., 2018) . (Yuan et al., 2017) . Exosomes derived from human umbilical cordmesenchymal stem cells improve inflammation in carbon tetrachoide (CCl4)-induced fibrosis in mouse livers (Li et al., 2013) . Mesenchymal stem cell-derived exosomes overexpressing GATA4 alleviate sequelae of ischemic heart disease via the anti-apoptotic miRNA, miR19a, which promotes mesenchymal stem cell differentiation in cardiomyocytes, reduces cardiomyocyte apoptosis and enhances angiogenesis (Yu et al., 2015) .

As part of their physiological function, exosomes are involved in the regulation of the immune system. Such exosomes derived from macrophages, dendritic cells and natural killer (NK) cells exhibit therapeutic effect by activating T cell responses and displaying anti-tumour effects in vitro (Andaloussi et al., 2013; Quah & O'Neill, 2005) . 

Exosome are defined by their cells of origin and their engineered

properties. However, their efficient and reliable production is controlled by their microenvironment, culture and dissociation systems. Further downstream steps in their manufacturing are also required involving isolation and characterisation. This process is generally divided into three steps:-(i) removing of cells and cell debris,

(ii) concentration of condition medium and (iii) purification Gao et al., 2020) .

Various types of cells have been used for good manufacturing practice exosome manufacturing such as HEK293 (Watson et al., 2018) , mesenchymal stem cells (Pachler et al., 2017) , dendritic cells (Lamparski et al., 2002) , adipose tissue-derived stem cells (Bari et al., 2019) and human cardiac progenitors cells (Andriolo et al., 2018) . Those cell types might require specific culture parameters such as the need for growth factors, oxygen requirements, cell density, cell passage and cell differentiation (Panchalingam et al., 2015; Patel et al., 2018; Sart et al., 2010) . The cultivation medium is usually defined into animal-free (Andriolo et al., 2018; Lamparski et al., 2002) or animal-derived (Mendt et al., 2018) components and is based on the type of cells used. However, for ethical issues and risks of contamination, animal-derived components should be avoided. The use of xeno-free conditions in good manufacturing practice production should be favoured as alternatives, xeno-free media has also been shown to increase yield (Andriolo et al., 2018) . The careful selection of a clone for further expansion is an option of choice: the clonal cell line will enable a homogeneous production and simplify the downstream characterisation process.

Culture systems include either static systems such as flasks, but scaling up processes will include dynamic systems like bioreactors which offer the advantage of improved controls of parameters such as CO 2 , O 2 and pH. Microcarriers in stirred-tanked bioreactors provide maximum surface area (Sart et al., 2010) and hollow fibre perfusion bioreactors (Yan & Wu, 2020) are also showing promising results.

Hollow fibre bioreactors (Watson et al., 2016) tend to be used for conditioned medium harvest (Mendt et al., 2018; Watson et al., 2018) . They also allow a more efficient production of exosomes compared with a static system. Dissociation enzymes if considered should be animal free (Andriolo et al., 2018) .

Downstream processing involves differential centrifugation, the most common method for media concentration. Exosome purification methods rely on density centrifugation, precipitation, chromatography, membrane filtration and size exclusion. Each method will influence the amount, type and purity of exosomes (Yang et al., 2019) .

Tangential flow filtration is another method recently developed for media concentration and exosome isolation and is proven to be more gentle, efficient and scalable than ultracentrifugation and resulting in higher yield. It combines membrane filtration and a tangential flow across the surface to avoid filter cake formation (Busatto et al., 2018) .

As clinical applications of exosomes expand, manufacturing strategies initially developed in academic settings need to be adapted for scaling up (Figure 3 ) to meet adequate Chemistry, Manufacturing and Controls (CMC) timelines and good manufacturing practice requirements. However, this scale-up process might alter the cell line phenotype and the downstream biological function of exosomes. For instance, this could impact the cellular microenvironment by modifying the cellular physiology, pH, oxygen supply, media composition and supply of growth factors (Chen et al., 2019) . Also, the use of primary or stem cell lines adds further complexity to the process (Cheng et al., 2017; Sart et al., 2010) as some cell lines like mesenchymal stem cells have slower growth and altered biology during the scale-up process (Chen et al., 2011) . Cell density, apoptotic blebs and impurities from cells undergoing cell death can further impact the exosome functionality (Bollini et al., 2013; Crescitelli et al., 2013; Patel et al., 2018) .

Scaling up using bioreactors can also have mechanical consequences.

mesenchymal stem cells, which have accrued potential for exosome production, can modify their cellular phenotype when exposed to shear stress in a bioreactor (Brindley et al., 2011; Panchalingam et al., 2015) . Cyclic stretch combined with shear stress inhibits their smooth muscle actin formation and induces a switch of mesenchymal stem cell phenotype towards endothelial cells (Patel et al., 2018) . An alternative to bioreactor is to use multiple flasks or stacked multilayer culture flasks, but this may not be a compatible option for industrial scale-up. One popular and cost-effective system is the Integra CELLine™ system, which allows high yield of exosomes compared to flasks without altering the exosome morphology, phenotype and function (Mitchell et al., 2008 ). The CELLine™ system uses different compartments for cells and media allowing a continuous flow of nutrients while reducing waste products and allowing optimal cell proliferation.

Another limiting factor for scaling up is the need of serum and growth factors in large volumes (Shelke et al., 2014) . Sera like fetal bovine serum are rich in endogenous exosomes and contaminants, a major pitfall for good manufacturing practice production. Furthermore, the drug-loading efficacy in exosomes is influenced by the production cell line, the cargo and the loading method and can vary from 1.4% to 38% (Walker et al., 2019) .

As extracellular vesicles are heterogeneous by nature, the purification process is critical, which limits the downstream scale-up.

Purification is frequently achieved using operator-dependent ultracentrifugation which produces low yields (Lee, Johansson, et al., 2019) . However, this challenge is progressively being overcome as illustrated by the production of good manufacturing practicecompliant mesenchymal stem cells-derived exosomes for clinical trials (Chen et al., 2019) . Additional purification steps are often required which include exclusion size chromatography and sucrose or Optiprep™ density gradients. Physical modification with the formation of exosome aggregates is also a significant drawback of ultracentrifugation as few reports suggest the exosome original phenotype and morphology to be compromised causing artefacts or undesired effects (Linares et al., 2015) . An adaptation of the rotor size and type (Cvjetkovic et al., 2014) can partly alleviate these detrimental effects.

Combined or as an alternative to ultracentrifugation, filtration and size exclusion chromatography methods are also commonly used for isolation. A promising technique combining bind-elution with size exclusion chromatography shows high yields and better reproducibility. This technology enables elution of large particles like exosomes while smaller impurities like nonvesicular proteins and RNAs remain bound to the column. It is highly reproducible generating up to 80% yields even when used with large volumes of media (Corso et al., 2017) while limiting risks of vesicular disruption and aggregation.

A safety regulatory framework with good manufacturing practice standards for exosome characterisation throughout the manufacturing process is being developed by the International Society for Extracellular Vesicles or the European Network on Macrovesicles and Exosomes in Health and Disease (Lener, Gimona, Aigner, Börger, Buzas, Camussi, Chaput, Chatterjee, Court, Portillo, & O'Driscoll, 2015a) . This standardisation is paramount for the clinical translation of exosomes (Ilic et al., 2012; Witwer et al., 2013) . Exosome characterisation includes (i) protein quantification using techniques such as bicinchoninic acid (BCA) assay, western blotting or liquid chromatography and mass spectrometry for proteomic analysis (Yang, Guo, et al., 2017) , size and concentration assessed by nanoparticle tracking analysis (Dragovic et al., 2011) , (ii) morphology by transmission electron microscopy (Chuo et al., 2018) and (iii) exosome surface profiling or cargo characterisation by flow cytometry and liquid chromatography or mass spectrometry (Schey et al., 2015) .

Finally, standardising storage methods of pure extracellular vesicle fractions is also a crucial step for translation (Mora et al., 2015 ) (Lener, Gimona, Aigner, Börger, Buzas, Camussi, Chaput, Chatterjee, Court, Portillo, O'Driscoll, Fais, et al., 2015b) . Storage at 4 C or −80 C can impact the biological activity and protein content of exosomes (Maroto et al., 2017) . Storage at −80 C is advised as the optimal temperature providing the least impact on exosome morphology and content (Yamashita et al., 2018) . Other parameters adding to the complexity of the scale-up process are the storage buffer and its pH, the number of freeze-thaw cycles and their effect on exosomal protein content (Cheng et al., 2019) .

Exosomes are poised at crossroads for clinical applications. The use of these small vesicles is rapidly expanding for diagnostic and therapeutic purposes following their relative recent discovery as key players in physiology and pathology. The leading clinical applications in cancer and inflammation are exploiting the exosome role in immunomodulation and its use as a vehicle for specific drug delivery. Numerous academic publications as well as high value investments in pharmaceutic development dedicated to the exosome field demonstrate general and cross-sector enthusiasm for these biotechnologies.

Various strategies to optimise the therapeutic efficacy of exosomes are being developed. The regulatory framework is evolving in order to allow safe and successful clinical trials. Improved scaling up strategies F I G U R E 3 Exosomes manufacturing for clinical use: from the laboratory to the industry. Schematic highlighting current differences between academic and industrial scale up. Exosomes can be derived from a cell bank or from the patients themselves. Laboratory set up predominantly uses a cell flask platform while the scaling up process involves bioreactors. While bioreactors increase yields and purity, exosomes need to be adequately characterised. FACS: fluorescence-activated cell sorting, LC/MS: liquid chromatography-mass spectrometry, MSC: mesenchymal stem cells, ME: microenvironment, NTA: nanoparticle tracking analysis are being developed in order to overcome the limitations of manufacturing and characterisation processes. Hence, while still at its infancy, the exosome field is moving fast to maturity for the benefit of the patients.

Key protein targets and ligands in this article are hyperlinked to corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-OGY http://www.guidetopharmacology.org and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 

The Concise Guide to PHARMACOLOGY 2019/2020: Nuclear hormones receptors

Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line

Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiology of Disease

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

Extracellular vesicles: Biology and emerging therapeutic opportunities

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas

Exosomes from human cardiac progenitor cells for therapeutic applications: Development of a GMP-grade manufacturing method

Exosomes and exosome-inspired vesicles for targeted drug delivery

Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy

Mesenchymal stromal cell secretome for severe COVID-19 infections: Premises for the therapeutic use

Freeze-dried and GMP-compliant pharmaceuticals containing exosomes for acellular mesenchymal stromal cell immunomodulant therapy

Exosomes are an effective vaccine against congenital toxoplasmosis in mice

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

The regenerative role of the fetal and adult stem cell secretome

Bioprocess forces and their impact on cell behavior: Implications for bone regeneration therapy

Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid

Activated T cells recruit exosomes secreted by dendritic cells via LFA-1

microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer

Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs

Exosomes in clinical trial and their production in compliance with good manufacturing practice

Exosomes in clinical trial and their production in compliance with good manufacturing practice

Focus on mesenchymal stem cell-derived exosomes: Opportunities and challenges in cellfree therapy

Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes

Quantitative and stoichiometric analysis of the microRNA content of exosomes

Imaging extracellular vesicles: Current and emerging methods

Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles

Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography

Distinct RNA profiles in subpopulations of extracellular vesicles: Apoptotic bodies, microvesicles and exosomes

Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/β-catenin signaling pathway

The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles

Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients

Immature myeloid cells induced by a high-fat diet contribute to liver inflammation

Recombinant retroviruslike particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development

A novel role of exosomes in the vaccination approach

Neutrophil membrane-derived nanovesicles alleviate inflammation to protect mouse brain injury from ischemic stroke

Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis

Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis

Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer

Detection of circulating miRNAs: Comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients

PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome

Generation, purification and engineering of extracellular vesicles and their biomedical applications

Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo

Therapeutic applications of extracellular vesicles: Clinical promise and open questions

Extracellular vesicles: Nature's nanoparticles for improving gene transfer with adeno-associated virus vectors

PIWI proteins and PIWI-interacting RNA: Emerging roles in cancer

Exosomes as drug delivery vehicles for Parkinson's disease therapy

Apoptotic endothelial cells release small extracellular vesicles loaded with immunostimulatory viral-like RNAs

Therapeutic use of mesenchymal stem cell-derived exosomes: From basic science to clinics

Exosomes released from breast cancer carcinomas stimulate cell movement

Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes

Mechanism of recipient cell-dependent differences in exosome uptake

Tumour exosome integrins determine organotropic metastasis

Exosomes in the pathology of neurodegenerative diseases

Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer

Nanoparticle analysis sheds budding insights into genetic drivers of extracellular vesicle biogenesis

Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: Part I-A method of manual documentary analysis

EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance

The biology, function, and biomedical applications of exosomes

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

CD24 is a marker of exosomes secreted into urine and amniotic fluid

Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting

DNA-containing exosomes derived from cancer cells treated with topotecan activate a STINGdependent pathway and reinforce antitumor immunity

CRISPR-Cas guides the future of genetic engineering

PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time

MSC-derived exosomes: A novel tool to treat therapyrefractory graft-versus-host disease

Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies

A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD

Production and characterization of clinical grade exosomes derived from dendritic cells

Role of pancreatic cancer-derived exosomes in salivary biomarker development

Dendritic cell-targeted pH-responsive extracellular vesicles for anticancer vaccination

Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion

Considerations and implications in the purification of extracellular vesicles-A cautionary tale

Exosomal α-synuclein as a biomarker for Parkinson disease

Applying extracellular vesicles based therapeutics in clinical trials-An ISEV position paper

Applying extracellular vesicles based therapeutics in clinical trials-An ISEV position paper

Transplantation of ACE2 − mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis

Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients

Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer

Exosomes: Novel biomarkers for clinical diagnosis

Highspeed centrifugation induces aggregation of extracellular vesicles

The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia

High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients

Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment

Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses

Unique somatic and malignant expression patterns implicate PIWI-interacting RNAs in cancer-type specific biology

Tumor-derived exosomes induce CD8 + T cell suppressors

A novel urine exosome gene expression assay to predict highgrade prostate cancer at initial biopsy

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

Generation and testing of clinical-grade exosomes for pancreatic cancer

Exosomes engineered to express a Cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo

Therapeutic potential of engineered extracellular vesicles

Pseudotyping exosomes for enhanced protein delivery in mammalian cells

Increased exosome production from tumour cell cultures using the Integra CELLine culture system

Effect of adipose-derived stem cells and their exo as adjunctive therapy to nonsurgical periodontal treatment: A histologic and histomorphometric study in rats

Biobanking of exosomes in the era of precision medicine: Are we there yet?

Routes and mechanisms of extracellular vesicle uptake

Combined treatment with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes

Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases

Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer

National Library of Medicine. Clinical trial database

A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression

Circulating exosomal microRNAs as biomarkers of colon cancer

Roles of exosomes and microvesicles in disease pathogenesis

Exosomes and their role in cancer progression

A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles

Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor

Bioprocessing strategies for the large-scale production of human mesenchymal stem cells: A review

Microenvironmental pH is a key factor for exosome traffic in tumor cells

Towards rationally designed biomanufacturing of therapeutic extracellular vesicles: Impact of the bioproduction microenvironment

Agerelated seroprevalence of antibodies against AAV-LK03 in a UK population cohort

Trafficking and function of the tetraspanin CD63

The immunogenicity of dendritic cellderived exosomes

Exosomal microRNA: A diagnostic marker for lung cancer

Alzheimer's disease beta-amyloid peptides are released in association with exosomes

Extracellular vesicles: Exosomes, microvesicles, and friends

Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery

EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells-A new option for the treatment of B-CLL

Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease

Exosome origin determines cell targeting and the transfer of therapeutic nanoparticles towards target cells

Influence of culture parameters on ear mesenchymal stem cells expanded on microcarriers

Proteomics characterization of exosome cargo

Role of stem cell derived exosomes in tumor biology

Importance of exosome depletion protocols to eliminate functional and RNAcontaining extracellular vesicles from fetal bovine serum

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5

Exosomes are natural carriers of exogenous siRNA to human cells in vitro

Piwis and piwi-interacting RNAs in the epigenetics of cancer

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

Microvesicles and exosomes for intracardiac communication

Isolation and identification of potential urinary microparticle biomarkers of bladder cancer

In vivo exosome based therapy for liver inherited metabolic disease: ASL deficiency

Tumor exosomes: A double-edged sword in cancer therapy

Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg)

Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer

Double-stranded DNA in exosomes: A novel biomarker in cancer detection

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

Exosomes: Composition, biogenesis and function

Exosomal miRNAs as cancer biomarkers and therapeutic targets

Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy

A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy

Ribonucleic artefacts: Are some extracellular RNA discoveries driven by cell culture medium components

Regulatory T cell-derived extracellular vesicles modify dendritic cell function

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

Role of exosomes in myocardial remodeling

Extracellular vesicle-based drug delivery systems for cancer treatment

Efficient production and enhanced tumor delivery of engineered extracellular vesicles

Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL-15/lactadherin complexes

Fetal bovine serum RNA interferes with the cell culture derived extracellular RNA

Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity

Exosome manufacturing status

Standardization of sample collection, isolation and analysis methods in extracellular vesicle research

Exosomes derived from gastric cancer cells activate NF-κB pathway in macrophages to promote cancer progression

Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8 + CTL responses through downregulation of peptide/MHC class I and Fas ligandmediated cytotoxicity

Possibility of exosomebased therapeutics and challenges in production of exosomes eligible for therapeutic application

Exosomes produced from 3D cultures of umbilical cord mesenchymal stem cells in a hollow-fiber bioreactor show improved osteochondral regeneration activity

Comprehensive proteomics analysis of exosomes derived from human seminal plasma

Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia

Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer

New insight into isolation, identification techniques and medical applications of exosomes

Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma

Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic micro-RNAs for cardioprotection

Mesenchymal stem cell-derived extracellular vesicles as a new therapeutic strategy for ocular diseases

The emerging roles of PIWIinteracting RNA in human cancers

TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy

The therapeutic and diagnostic role of exosomes in cardiovascular diseases

HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing

The expression of stem cell protein Piwil2 and piR-932 in breast cancer

Exosomes: Biogenesis, biologic function and clinical potential

Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord bloodderived multipotent stem cells

Urinary exosomal transcription factors, a new class of biomarkers for renal disease

Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming

Exosome redux

Clinical applications for exosomes: Are we there yet?

All authors revised substantially and approved the final manuscript. All authors accept full responsibility of its content.

The authors are partially funded by a United Kingdom Research Council Innovate UK Biomedical Catalyst award (14720) awarded jointly with Evox Therapeutics.

https://orcid.org/0000-0003-0582-540X